{"url_path":"/sec/bdtx/8-k/2026-05-21/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1701541/0001104659-26-065254-index.html","accession_number":"0001104659-26-065254","cik":"0001701541","ticker":"BDTX","issuer_name":"Black Diamond Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701541/0001104659-26-065254-index.html","primary_entity_key":"0001701541","primary_entity_name":"Black Diamond Therapeutics, Inc."},"word_count":145,"has_tables":true,"body_markdown":"**Item 7.01. Regulation FD Disclosure.**\n\n \n\nOn May 21, 2026, Black Diamond Therapeutics, Inc.\n(the “Company”) issued a press release titled “Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib\nin Frontline NSCLC Patients with EGFR Non-Classical Mutations.” A copy of the press release is furnished as Exhibit 99.1 to\nthis Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe information in this Item 7.01, including Exhibit 99.1\nattached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities\nExchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall\nit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly\nset forth by specific reference in such a filing."}